Cornelli, U., Terranova, R., Luca, S., Cornelli, M
Extracellular vesicles in breast cancer: from intercellular communication to therapeutic opportunities
The details of Celltrion's abstracts are as follows: Abstract TitlePresentation DetailsAll times CTPROFILE 4-year follow-up shows that earlyeffective "top-down" therapy is associated withreduced long-term Crohn's disease complications Oral PresentationLate Breakers in IBDTuesday, May 5, 2026/ 10:00 AM 10:15 AM Randomised controlled trial of withdrawal ofthiopurines in patients with IBD switching fromintravenous to subcutaneous infliximab: Resultsof the MINIMISE study Oral PresentationIBD: Controlled Clinical Trials 2Tuesday, May 5, 2026/ 8:30 AM 8:45 AM Randomised controlled trial of continuedintravenous versus switching to subcutaneousinfliximab in inflammatory bowel disease: theSubcutaneous Infliximab Switch Study (SISS) Oral PresentationIBD: Controlled Clinical Trials 2Tuesday, May 5, 2026/ 8:00 AM8:15 AM Comparison of effectiveness betweensubcutaneous infliximab as monotherapy orcombined with an immunosuppressant in patientswith Crohn's disease: interim results from theREMONO-CD study Oral Presentation #537Comparative Effectiveness in IBDSunday May 3, 2026 / 4:30PM 4:45PM Long-term effectiveness, safety, acceptability, andprogression of bowel damage of switching fromintravenous to subcutaneous infliximab inpatients with inflammatory bowel diseasestreated with intensified doses: The REMSWITCH-VLT study Oral PresentationAdvances in Medical Therapy of IBDTuesday, May 5, 2026/ 4:45 PM 5:00 PM Recapturing disease control with subcutaneousinfliximab after a drug holiday followingintravenous infliximab induction: A post hocanalysis of LIBERTY-CD and -UC studies Poster PresentationInflammatory Bowel Disease ePoster ShowcaseSunday, May 3, 2026/11:57 AM 12:03 PM Subcutaneous infliximab (CT-P13 SC) asmaintenance therapy for Crohn's disease in Japan:Safety and efficacy over 44 weeks ePoster (online only) Notes to Editors: About ZYMFENTRA (infliximab-dyyb) ZYMFENTRA (infliximab-dyyb) is a prescription medicine used as an injection under the skin (subcutaneous injection) by adults for the maintenance treatment of moderately-to-severely active ulcerative colitis following treatment with an infliximab product given by intravenous infusion (IV), Moderately-to-severely active Crohn's disease following treatment with an infliximab product given by intravenous infusion (IV)
Mice that lack of autophagic activity due to various ATG knockouts either die in utero or within 24 h after birth [3,4,5]
